MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letter”) on March 31, 2023 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million (the “Stockholders’ Equity Requirement”).

Go here to read the rest:
Celyad Oncology announces receipt of Nasdaq notice

HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.

Read this article:
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee.

Go here to see the original:
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies today announced that the Company entered into the warrant agreement (the “Warrant Agreement”) and finalized the related ancillary documents required under the credit facility with the European Investment Bank (“EIB”) (the "Finance Contract") for up to €40 million previously announced on December 28, 2022. The Company also announced the drawdown of the first tranche of €20 million (“Tranche A”) under the Finance Contract, expected to be disbursed by the EIB in early April 2023. The Company plans to use the proceeds of Tranche A towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.

More:
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first...

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes of SARS-CoV-2. The program aims to serve as proof-of-concept for Gritstone’s infectious disease vaccine approach and the potential application of samRNA against infectious diseases.

See original here:
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

View post:
INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379 Oslo, at 14:00 CET on 20 April 2023.

Go here to read the rest:
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

Read this article:
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

SAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

Read more:
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned with environmental responsibility and reversing climate change -

View original post here:
Grace Breeding Reports 2022 Full-Year Financial Results

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers

Read the original:
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients

Read more:
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported fourth quarter and full year 2022 financial results and provided an update on its business.

Follow this link:
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.

Read more from the original source:
Abeona Therapeutics Announces New Employee Inducement Grants

Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization

See the original post:
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Continue reading here:
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’s progress.

See the original post:
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022

See the article here:
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

Here is the original post:
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide.

Link:
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER...